# Divalent HIV-1 gp120 Immunogen Exhibits Selective Avidity for Broadly Neutralizing Antibody VRC01 Precursors

## TL;DR

Researchers designed a rigid HIV immunogen that binds strongly to a key antibody, which could help in developing better vaccines.

## Contribution

The study introduces a novel rigid divalent immunogen with selective avidity for VRC01-class antibodies.

## Key findings

- The rigid immunogen shows higher affinity for VRC01 antibodies compared to a flexible control.
- The immunogen binds divalently to VRC01 and monovalently to non-CD4bs antibodies.
- The design may have broad applications for immune focusing in vaccine development.

## Abstract

Background: A major goal for the vaccine field is the elicitation of broadly neutralizing antibodies (bnAbs) against pathogens that exhibit extensive antigenic diversity. Methods: In this study, we designed a rigid divalent immunogen for high avidity binding to the bnAb, VRC01, which targets the CD4 binding site (CD4bs) of the HIV spike protein. This was accomplished by covalently linking two HIV-1 gp120 antigens to a complementary antibody and crosslinking the light chains. Binding kinetics were analyzed using a novel gel shift assay and surface plasmon resonance. Results: The rigid divalent immunogen exhibits a higher affinity for VRC01-class antibodies compared to a flexible control, likely due to antigen pre-organization limiting the entropic penalty for divalent binding. Crucially, this immunogen exhibited divalent binding to VRC01 and monovalent binding to a non-CD4bs Ab, A32—a characteristic we refer to as “selective avidity.” Conclusions: In light of these results, we are preparing for in vivo vaccination experiments to test the immune focusing properties of this immunogen, the results of which may suggest broad application of the selective avidity concept.